000186695 001__ 186695
000186695 005__ 20240229154902.0
000186695 0247_ $$2doi$$a10.3322/caac.21768
000186695 0247_ $$2pmid$$apmid:36622841
000186695 0247_ $$2ISSN$$a0007-9235
000186695 0247_ $$2ISSN$$a1542-4863
000186695 0247_ $$2altmetric$$aaltmetric:141022252
000186695 037__ $$aDKFZ-2023-00064
000186695 041__ $$aEnglish
000186695 082__ $$a610
000186695 1001_ $$00000-0003-2276-6771$$aAboagye, Eric O$$b0
000186695 245__ $$aRadiotheranostics in oncology: Making precision medicine possible.
000186695 260__ $$aHoboken, NJ$$bWiley$$c2023
000186695 3367_ $$2DRIVER$$aarticle
000186695 3367_ $$2DataCite$$aOutput Types/Journal article
000186695 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683729813_9239$$xReview Article
000186695 3367_ $$2BibTeX$$aARTICLE
000186695 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186695 3367_ $$00$$2EndNote$$aJournal Article
000186695 500__ $$a#LA:E060# / 2023 May-Jun;73(3):255-274
000186695 520__ $$aA quintessential setting for precision medicine, theranostics refers to a rapidly evolving field of medicine in which disease is diagnosed followed by treatment of disease-positive patients using tools for the therapy identical or similar to those used for the diagnosis. Against the backdrop of only-treat-when-visualized, the goal is a high therapeutic index with efficacy markedly surpassing toxicity. Oncology leads the way in theranostics innovation, where the approach has become possible with the identification of unique proteins and other factors selectively expressed in cancer versus healthy tissue, advances in imaging technology able to report these tissue factors, and major understanding of targeting chemicals and nanodevices together with methods to attach labels or warheads for imaging and therapy. Radiotheranostics-using radiopharmaceuticals-is becoming routine in patients with prostate cancer and neuroendocrine tumors who express the proteins PSMA (prostate-specific membrane antigen) and SSTR2 (somatostatin receptor 2), respectively, on their cancer. The palpable excitement in the field stems from the finding that a proportion of patients with large metastatic burden show complete and partial responses, and this outcome is catalyzing the search for more radiotheranostics approaches. Not every patient will benefit from radiotheranostics; but, for those who cross the target-detected line, the likelihood of response is very high.
000186695 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000186695 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186695 650_7 $$2Other$$ametastatic cancer
000186695 650_7 $$2Other$$amolecularly targeted therapies
000186695 650_7 $$2Other$$anuclear medicine
000186695 650_7 $$2Other$$apharmacology
000186695 650_7 $$2Other$$apositron emission tomography
000186695 650_7 $$2Other$$aradioisotopes
000186695 650_7 $$2Other$$aradiotheranostics
000186695 650_7 $$2Other$$atheranostics audit trail
000186695 7001_ $$aBarwick, Tara D$$b1
000186695 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b2$$eLast author$$udkfz
000186695 773__ $$0PERI:(DE-600)2018502-9$$a10.3322/caac.21768$$gp. caac.21768$$n3$$p255-274$$tCA$$v73$$x0007-9235$$y2023
000186695 909CO $$ooai:inrepo02.dkfz.de:186695$$pVDB
000186695 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000186695 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000186695 9141_ $$y2023
000186695 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-30
000186695 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-30
000186695 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCA-CANCER J CLIN : 2022$$d2023-10-22
000186695 915__ $$0StatID:(DE-HGF)9990$$2StatID$$aIF >= 90$$bCA-CANCER J CLIN : 2022$$d2023-10-22
000186695 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000186695 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000186695 980__ $$ajournal
000186695 980__ $$aVDB
000186695 980__ $$aI:(DE-He78)E060-20160331
000186695 980__ $$aUNRESTRICTED